Changes in mRNA Expression Following Exposure to Naproxen
Overview
Using tissue samples obtained from a previous study, the effect of naproxen on the gene expression profiles of antral mucosal tissue will be assessed. We hypothesize that there will be distinct changes in the gene expression profiles of samples taken from individuals treated with naproxen versus samples taken from individuals treated with placebo.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Primary Purpose: Basic Science
- Masking: Double (Participant, Investigator)
- Study Primary Completion Date: June 2008
Detailed Description
We will use microarray technology to quantify the transcriptome-wide changes in gene expression in said-samples.
Interventions
- Drug: Naproxen
- 500mg naproxen, twice daily for 7 days
- Drug: Placebo
- 1 tab,twice a day for a seven days
Arms, Groups and Cohorts
- Active Comparator: Naproxen-Treated
- Placebo Comparator: placebo
Clinical Trial Outcome Measures
Primary Measures
- Fold Change in Gene Expression
- Time Frame: 7 days
Participating in This Clinical Trial
Inclusion Criteria
- Healthy adult between the ages of 18 and 75 inclusive – Written informed consent prior to undergoing any study procedures – A physical examination which reveals no clinically significant abnormalities – Female subjects of childbearing potential must be taking an acceptable form of contraceptive Exclusion Criteria:
- Any mucosal breaks within 2 cm of pyloric channel seen on baseline endoscopy – Any GDU or >5 gastroduodenal erosions at baseline endoscopy – CXB, CPG, ASA, or NS-NSAID use within the prior 2 weeks – Previous gastrointestinal ulcer – Hypersensitivity or allergy to NSAIDs, ASA, CPG, CXB or other contraindication to taking treatments – Baseline complaints of abdominal pain, nausea, and/or cramping – Any acid blocking medication including antacids, H-2 receptor blocker within the prior 2 weeks, or PPI use within the prior 30 days – Corticosteroids use within the prior 60 days – Any documented bleeding tendency – Has taken warfarin within the prior 60 days – Three or greater alcoholic beverages daily – History of cerebro-vascular event
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 75 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Research Associates of New York, LLP
- Provider of Information About this Clinical Study
- James Aisenberg, MD, Research Associates of New York
- Overall Official(s)
- James Aisenberg, MD, Principal Investigator, Research Associates of New York
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.